<ul><li><a class="l" href="#pf1" data-dest-detail='[1,"FitR",0,696,584,672]'> Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer</a><ul><li><a class="l" href="#pf1" data-dest-detail='[1,"FitR",0,165,584,153]'>Introduction</a></li><li><a class="l" href="#pf2" data-dest-detail='[2,"FitR",0,325,389,315]'>Materials and Methods</a><ul><li><a class="l" href="#pf2" data-dest-detail='[2,"FitR",0,305,389,294]'>Study Design and Treatment</a></li><li><a class="l" href="#pf2" data-dest-detail='[2,"FitR",0,98,389,87]'>Patients</a></li><li><a class="l" href="#pf2" data-dest-detail='[2,"FitR",195,600,584,589]'>Study Endpoints and Tumor Assessments</a></li><li><a class="l" href="#pf2" data-dest-detail='[2,"FitR",195,485,584,474]'>Statistical Analysis</a></li><li><a class="l" href="#pf2" data-dest-detail='[2,"FitR",195,84,584,73]'>Biomarker Analysis</a></li></ul></li><li><a class="l" href="#pf3" data-dest-detail='[3,"FitR",0,532,389,522]'>Results</a><ul><li><a class="l" href="#pf3" data-dest-detail='[3,"FitR",0,512,389,501]'>Patient Characteristics</a></li><li><a class="l" href="#pf3" data-dest-detail='[3,"FitR",0,397,389,386]'>Treatment and Outcomes</a></li><li><a class="l" href="#pf3" data-dest-detail='[3,"FitR",0,98,389,87]'>Toxicity</a></li><li><a class="l" href="#pf3" data-dest-detail='[3,"FitR",195,298,584,286]'>Genomic Analysis</a></li></ul></li><li><a class="l" href="#pf4" data-dest-detail='[4,"FitR",0,132,389,121]'>Discussion</a></li><li><a class="l" href="#pf6" data-dest-detail='[6,"FitR",0,406,389,395]'>Conclusion</a></li><li><a class="l" href="#pf6" data-dest-detail='[6,"FitR",195,624,584,614]'>Acknowledgments</a></li><li><a class="l" href="#pf6" data-dest-detail='[6,"FitR",195,488,584,478]'>Author Contributions</a></li><li><a class="l" href="#pf6" data-dest-detail='[6,"FitR",195,235,584,224]'>Disclosures</a></li><li><a class="l" href="#pf6" data-dest-detail='[6,"FitR",0,108,584,96]'>References</a></li></ul></li></ul>